According to the above findings, we reasoned the poor response to immunotherapies in CRC may be in part due to the presence of mutant KRAS causing a reduction of tumor‐infiltrating cytotoxic CD8+ T‐cells. The gene discussed is KRAS; the disease is neoplasm.